"Children and adults who inadvertently consume a higher dose of clonazepam could be at increased risk for the adverse events ...

The company is worried mislabeling could lead to unintentionally taking higher doses and adverse side effects.

"Clonazepam Orally Disintegrating Tablets, USP (C-IV)" on November 18th, due to "potential product carton strength ...

This past July, we reported on the Centers for Medicare & Medicaid Services (CMS) release of the 2025 proposed Hospital Outpatient Prospective ...

French company looks to rein in how it gives discounts in federal program designed to help hospitals that serve low-income ...

Sanofi's new plan will take effect early next year and will require institutions to provide pharmacy and medical claims ...

Sanofi (SNY) is planning changes to its 340B plan on how it gives discounts to certain hospitals, planning to require institutions to provide ...

In today's biotech news, Prime Editing's CEO promises aggressive defense of patents; Novartis acquires a gene editing startup ...

Endo, Inc., has expanded its voluntary recall of Clonazepam Orally Disintegrating Tablets, USP (C-IV) due to mislabeled ...